Trial Profile
Analysis of efficacy and safety of antiviral therapy with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2016
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 20 Dec 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 22 Aug 2014 New trial record